Calcitonin Receptor is a Novel Biomarker for NF-κB-Mediated Cellular Stress in Triple-Negative Breast Cancer Cells
Frontiers in Bioscience-Landmark · 24.04.2026 · 31 (4)
DOI: 10.31083/fbl50148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 24.04.2026. Verfasst von Hanieh Heydarlou und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, College of Health, Adelaide University, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, NF-kappa B, Receptors, Calcitonin, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council of Australia, Australian Government Research Training Program (RTP) Scholarship, Supplementary scholarships from The Hospital Research Foundation Group.
Abstract (Originalsprache)
Background
Cellular stress can arise from external and internal stimuli and induce mechanisms that either maintain survival or activate cell death pathways. Nuclear factor kappa B (NF-κB) is a key transcription factor that mediates a range of responses to cellular stress, including senescence, DNA repair, and inflammation in breast cancer; however, there are currently limited biomarkers that identify its activation. CalRexinTM, a monoclonal antibody that targets the human calcitonin receptor, was investigated as a novel biomarker for cell stress associated with NF-κB activation.
Methods
Triple-negative breast cancer cell lines MDA-MB-231 and MDA-MB-468 were treated with lipopolysaccharide (LPS) to induce NF-κB-mediated cellular stress or treated with the cytotoxin staurosporine to induce apoptosis as a positive control. CalRexinTM and Annexin V positivity were investigated by flow cytometry and immunofluorescence.
Results
Flow cytometry analysis revealed a dose- and time-dependent increase in the mean fluorescence intensity of CalRexinTM following LPS treatment of breast cancer cells. The mean fluorescence intensity of Annexin V, as a marker of apoptosis was not increased by LPS treatment and the cells remained viable. Immunofluorescence imaging demonstrated CalRexinTM positivity in LPS-stimulated cells accompanied by nuclear translocation of NF-κB.
Conclusion
Increased expression of calcitonin receptor, identified using the novel CalRexinTM antibody, has potential use as a biomarker for NF-κB-mediated cellular stress in breast cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, College of Health, Adelaide University, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia.
- Robinson Research Institute, Adelaide University, Adelaide, SA 5005, Australia.
- Department of Medicine-Austin, University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia.
- Medical Oncology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia.
Förderung
- National Health and Medical Research Council of Australia
- Australian Government Research Training Program (RTP) Scholarship
- Supplementary scholarships from The Hospital Research Foundation Group
Zitieren
APA
Heydarlou, H., Maleki, R., Wookey, P. J., Smith, E., & Ingman, W. V. (2026). Calcitonin Receptor is a Novel Biomarker for NF-κB-Mediated Cellular Stress in Triple-Negative Breast Cancer Cells. Frontiers in Bioscience-Landmark, 31(4). https://doi.org/10.31083/fbl50148
Vancouver
Heydarlou H, Maleki R, Wookey PJ, Smith E, Ingman WV. Calcitonin Receptor is a Novel Biomarker for NF-κB-Mediated Cellular Stress in Triple-Negative Breast Cancer Cells. Frontiers in Bioscience-Landmark. 2026;31(4). doi:10.31083/fbl50148
BibTeX
@article{Heydarlou2026,
author = {Heydarlou, Hanieh and Maleki, Reza and Wookey, Peter J and Smith, Eric and Ingman, Wendy V},
title = {Calcitonin Receptor is a Novel Biomarker for NF-κB-Mediated Cellular Stress in Triple-Negative Breast Cancer Cells},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {4},
doi = {10.31083/fbl50148}
}
EUVIMED